Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04169152
Other study ID # CAES-CN-191111
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 30, 2019
Est. completion date June 30, 2028

Study information

Verified date April 2024
Source The Second Hospital of Nanjing Medical University
Contact Faming Zhang, MD,PhD
Phone 02558509884
Email fzhang@njmu.edu.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Cap-assisted endoscopic sclerotherapy (CAES) is a new interventional therapy for internal hemorrhoids and rectal prolapse under colonoscopy. However, the long-term efficacy and safety of CAES in the treatment of internal hemorrhoids and rectal prolapse are still not clear due to the lack of large sample studies. Therefore, a nationwide multi-center, large sample, prospective and cohort study was designed to evaluate the efficacy and safety of CAES in the treatment of internal hemorrhoids and rectal prolapse, to provide reliable evidence for popularization of this minimally invasive technology.


Description:

CAES is an innovative endoscopic sclerotherapy procedure which is different from traditional method. Firstly, the cap added to the front of colonoscope can fully expose the operating field. Secondly, before or during the opportunity of CAES, endoscopist can perform endoscopic differentiation diagnosis (such as tumors, inflammatory bowel disease and others induced hematochezia), endoscopic therapy within lower-gut based on the same colon preparation, thus saving patients' medical cost, physical and mental pain. The last but not least, specially designed length of endoscopic injection needle (eg.10-20 mm) was used in CAES could be helpful for accurately controlling the injection angle, direction, depth under direct vision and to avoid iatrogenic injury due to ectopic injection.The core value of CAES for internal hemorrhoids and rectal prolapse is to provide precise therapy, reduce the iatrogenic injuries, avoid pain during and after therapy. Our pilot studies demonstrated that CAES based on long injection needle is an effective, safe, convenient operation technique. 100% of participants underwent CAES showed sustained clinical efficacy within the 3-month follow-up, with no severe or obvious complications related to CAES. However, the long-term efficacy and safety of CAES in the treatment of internal hemorrhoids and rectal prolapse need to be confirmed by further large sample real world studies.


Recruitment information / eligibility

Status Recruiting
Enrollment 10000
Est. completion date June 30, 2028
Est. primary completion date December 30, 2027
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: 1. Grade I-III internal hemorrhoids (with or without external hemorrhoids) or/and recal prolapse. 2. Patients with bowel preparation. Exclusion Criteria: 1. History of anoscopic/endoscopic sclerotherapy. 2. Acute thrombotic hemorrhoids or grade IV internal hemorrhoids. 3. Anal stenosis, perianal and perirectal abscess, anal fissure, fistula, fecal incontinence and other severe complications (such as severe anal pain). 4. Inflammatory bowel disease. 5. Full-thickness rectal prolapse through the anus. 6. Acute diarrhea in the past 24 hours. 7. Hypertensive with uncontrolled blood pressure. 8. Cerebrovascular accident. 9. Blood coagulation dysfunction. 10. Pregnant women. 11. Mental disorders. 12. Decompensated cirrhosis.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Cap-assisted endoscopic sclerotherapy
Cap-assisted endoscopic sclerotherapy (CAES) is an innovation technique for having advantages in accurately controlling the injection angle, direction, depth under direct vision of flexible endoscope.

Locations

Country Name City State
China Medical Center for Digestive Diseases, Second Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Faming Zhang

Country where clinical trial is conducted

China, 

References & Publications (3)

Tokunaga Y. Clinical utility of sclerotherapy with a new agent for treatment of rectal prolapse in patients with risks. J Clin Gastroenterol. 2014 Apr;48(4):356-9. doi: 10.1097/MCG.0b013e318299cab8. — View Citation

Tomiki Y, Ono S, Aoki J, Takahashi R, Sakamoto K. Endoscopic sclerotherapy with aluminum potassium sulfate and tannic acid for internal hemorrhoids. Endoscopy. 2014;46 Suppl 1 UCTN:E114. doi: 10.1055/s-0034-1364884. Epub 2014 Mar 27. No abstract available. — View Citation

Zhang T, Xu LJ, Xiang J, He Z, Peng ZY, Huang GM, Ji GZ, Zhang FM. Cap-assisted endoscopic sclerotherapy for hemorrhoids: Methods, feasibility and efficacy. World J Gastrointest Endosc. 2015 Dec 25;7(19):1334-40. doi: 10.4253/wjge.v7.i19.1334. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Recurrence rate Recurrence rate defined as the proportion of patients with recurrent hemorrhoids at 24 weeks post-CAES, as derived from patients' self-reported answer. Patients will be considered to have recurrent hemorrhoids when any of the following are recorded: (1) "Unchanged or worse compared with before starting treatment" at 24th week as reported by the patient, or (2) seeking repeat CAES treatment, alternative non-surgical/surgical treatments for internal hemorrhoids within 24weeks (except medication treatment), or (3) presence of any symptoms or events that strongly indicated recurrent hemorrhoids among patients not meeting (1) or (2). 1st week to 24th week
Secondary Improvement rate Bleeding, prolapse, and anal pain had resolved or remitted after CAES. Bleeding is divided into three degrees: 1. No bleeding; 2. 2: occasionally; 3: quite often.There are three degrees of prolapse: 1. No prolapse; 2: occasionally; 3: quite often.NRS pain digital rating scale was adopted, that is, 0-10 was used to represent different degrees of pain, 0 was painless, and 10 was severe pain. 0 painless, 1-3 mild pain (pain does not affect sleep), 4-6 moderate pain, 7-9 severe pain (inability to fall asleep or waking up during sleep), 10 severe pain. 1st day, 1st week, 2nd week and 24th week
Secondary Failure rate Bleeding, prolapse, and anal pain remained the same after CAES. Bleeding is divided into three degrees: 1. No bleeding; 2. 2: occasionally; 3: quite often.There are three degrees of prolapse: 1. No prolapse; 2: occasionally; 3: quite often.NRS pain digital rating scale was adopted, that is, 0-10 was used to represent different degrees of pain, 0 was painless, and 10 was severe pain. 0 painless, 1-3 mild pain (pain does not affect sleep), 4-6 moderate pain, 7-9 severe pain (inability to fall asleep or waking up during sleep), 10 severe pain. 1st day, 1st week, 2nd week and 24th week
Secondary Three-level EuroQol five dimensions (ED-5Q) health scale scores The ED-5Q questionnaire includes five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), with three levels in each dimension (no/moderate/severe problem). Through the Chinese time trade-off (TTO) value table, the health status of five dimensions will be converted into a preference weight of a ED-5Q index score for further analysis. 24th week
Secondary Adverse events (AEs) AEs refer to adverse medical events that occurs during or after CAES, including bleeding, anal pain, having difficulties in passing gas and defecation, infection, ulcer/bleeding in the injection points under endoscopic examination (5-7 days after CAES) and other symptoms. 1st day, 1st week, 2nd week and 24th week
Secondary severe adverse events (SAEs) severe adverse events (SAEs) severe adverse events (SAEs) Severe adverse events (SAEs) SAEs include serious complications directly or indirectly related to the CAES, such as death, bleeding, perforation, infection. 1st day, 1st week, 2nd week and 24th week
Secondary Participants' attitudes toward CAES The survey on the satisfaction with CAES efficacy, and the willingness to recommend CAES to others. 24th week
Secondary Symptom severity score Symptom severity score: five questions about hemorrhoidal symptoms (anal pain, prolapse, itching, soiling, and blood loss) will be self-assessed by patients by answering how often each symptom was encountered (never, sometimes, weekly, or daily). The score is the sum of the points from all five questions, ranging from 0 to 15 points, where an increase in number is an increase in symptom. 1day and 24 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05918367 - Multicenter Ventral Mesh Rectopexy Registry Collaborative
Completed NCT00946205 - Laparoscopic Rectopexy for Rectal Prolapse N/A
Not yet recruiting NCT06455501 - FOAM: Functional Outcome After Ventral Mesh Rectopexy
Completed NCT02609555 - TEM Assisted Perineal Rectopexy in Treatment of Rectal Prolapse N/A
Recruiting NCT01880918 - A RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing N/A
Completed NCT01056913 - NITI CAR27 (ColonRing) Compression Anastomosis in Colorectal Surgery Phase 4
Completed NCT06353230 - Comparison of Sclerotherapy Agents Used for Rectal Prolapse Treatment in Children N/A
Completed NCT05254860 - Continuous Locked Non-barbed Suture for Mesh Fixation During Laparoscopic Ventral Rectopexy for Severe Rectal Prolapse N/A
Recruiting NCT01992406 - Feasibility, Safety and Outcome of Transrectal Hybrid-NOTES Anterior Resection N/A
Active, not recruiting NCT06330857 - Recurrence and Bowel Function After Laparoscopic Vaginorectopexy, a Modified Anterior Rectopexy N/A
Completed NCT01980043 - Endoluminal and Needlescopic Assisted Repair of Rectal Prolapse N/A
Completed NCT03643393 - Report 2 Cases of Massive Incarceration Necrosis Rectal Prolapse Are Successfully Treated With Altemeier's Procedure N/A
Completed NCT04627610 - Recurrence of Dyschezia in Rectal Prolapse, Rectocele and Elytrocele
Terminated NCT04893642 - Swedish Rectal Prolapse Trial N/A
Recruiting NCT04817150 - 3D vs 2D-laparoscopy for Rectocele and Rectal Prolapse Correction: a Prospective, Randomized, Single Center Study N/A
Enrolling by invitation NCT05728554 - Breakthrough Improvement Collaborative for Ventral Mesh Rectopexy
Recruiting NCT03917056 - Cap-assisted Endoscopic Sclerotherapy for Internal Hemorrhoids and Rectal Prolapse N/A
Completed NCT02971332 - Long Term Results of STARR With Contour Transtar N/A
Active, not recruiting NCT04013152 - Clinical Database of Colorectal Robotic Surgery
Recruiting NCT06245577 - Biological Mesh Versus Synthetic Mesh in Interdisciplinary RRP With SCP N/A